title: [Detection of B19 parvovirus in plasma pools before solvent-detergent treatment of plasma: AFSSAPS and EFS Aquitaine-Limousin's experience].
abstract: Since 1998, the Aquitaine-Limousin branch of the French Blood Institute has set up a parvovirus B19 (PV B19) systematic screening on each unit of plasma to be treated by solvent-detergent procedure for virus inactivation. Parvovirus B19 nucleic acid systematic testing in plasma pools became mandatory since 2005 (European monograph "Human plasma" - pooled and treated for virus inactivation). The French competent state authority (AFSSAPS) has decided to introduce this test as a part of the external quality control of labile blood products. This process is related to the harmonization of quality control practice realised on blood products in Europe even if the human plasma pooled and treated for virus inactivation by solvent-detergent is considered in France as a blood labile component. Implementation of this test required a validation step and a close cooperation between AFSSAPS and Aquitaine-Limousin blood transfusion centre. Validation consisted in perfecting a semi-quantitative, real-time nucleic acid testing method with automated extraction. This collaborative study leads us to control 1642 plasma pools. All the results were under the threshold of 10,0 IU/microL. AFSSAPS's results were in agreement with those of Aquitaine-Limousin's blood transfusion center who carry out the parvovirus B19 screening both on fresh frozen plasma units composing the pool and on plasma pools.
authors.affiliation: Agence française de sécurité sanitaire des produits de santé, 143-147, boulevard Anatole-France, 93285 Saint-Denis, France. rachel.petermann@afssaps.sante.fr
authors.forename: R
authors.initials: R
authors.lastname: Petermann
authors.forename: Y
authors.initials: Y
authors.lastname: Piquet
authors.forename: M
authors.initials: M
authors.lastname: Lapeyre
authors.forename: N
authors.initials: N
authors.lastname: Goujon
authors.forename: M
authors.initials: M
authors.lastname: Gauthier
authors.forename: V
authors.initials: V
authors.lastname: Lalanne
authors.forename: L
authors.initials: L
authors.lastname: Mouillot
authors.forename: M H
authors.initials: MH
authors.lastname: Tissier
authors.forename: J-M
authors.initials: JM
authors.lastname: Boiron
mesh_terms: D001782:Blood Donors; D058731:Blood Safety / Q000379:methods*; D004279:DNA, Viral / Q000097:blood* / Q000302:isolation & purification; D003902:Detergents; D005602:France; D006801:Humans; D015994:Incidence; D010322:Parvoviridae Infections / Q000097:blood / Q000453:epidemiology* / Q000517:prevention & control; D016732:Parvovirus B19, Human / Q000302:isolation & purification*; D010949:Plasma / Q000821:virology*; D016133:Polymerase Chain Reaction / Q000379:methods*; D015203:Reproducibility of Results; D012680:Sensitivity and Specificity; D012955:Societies, Medical; D012997:Solvents; D014766:Viremia / Q000453:epidemiology*; D038301:Virus Inactivation
chemical_list: D004279:DNA, Viral; D003902:Detergents; D012997:Solvents